These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29182383)

  • 1. Ovarian cancer: how can resistance to chemotherapy be tackled?
    Karakashev S; Aird KM
    Future Oncol; 2017 Dec; 13(30):2737-2739. PubMed ID: 29182383
    [No Abstract]   [Full Text] [Related]  

  • 2. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
    Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
    Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drugs for old targets.
    Salles G
    Hematol Oncol; 2019 Jun; 37 Suppl 1():101-104. PubMed ID: 31187537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of chemotherapy resistance in ovarian cancer.
    Cooley M; Fang P; Fang F; Nephew KP; Chien J
    Pharmacogenomics; 2015 Nov; 16(16):1763-7. PubMed ID: 26554863
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapy of ovarian cancer including immune check point inhibitor.
    Kim JY; Cho CH; Song HS
    Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemoresistance in ovarian cancer. State of the art and future prospects].
    Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
    Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?
    Assi T
    Future Oncol; 2019 Oct; 15(28):3185-3187. PubMed ID: 31578878
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic approaches to overcoming chemoresistance in ovarian cancer.
    Suh DH; Kim MK; No JH; Chung HH; Song YS
    Ann N Y Acad Sci; 2011 Jul; 1229():53-60. PubMed ID: 21793839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent ovarian cancer.
    Pujade-Lauraine E; Combe P
    Ann Oncol; 2016 Apr; 27 Suppl 1():i63-i65. PubMed ID: 27141075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors in ovarian and other cancers.
    Plummer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
    [No Abstract]   [Full Text] [Related]  

  • 13. New drugs in ovarian cancer.
    Fleming GF
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):223-5. PubMed ID: 26352580
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of membrane transporters in ovarian cancer chemoresistance and prognosis.
    Cerovska E; Elsnerova K; Vaclavikova R; Soucek P
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):741-753. PubMed ID: 28511565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defective apoptosis underlies chemoresistance in ovarian cancer.
    Hajra KM; Tan L; Liu JR
    Adv Exp Med Biol; 2008; 622():197-208. PubMed ID: 18546629
    [No Abstract]   [Full Text] [Related]  

  • 16. Recently identified drug resistance biomarkers in ovarian cancer.
    Davidson B
    Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer: beyond resistance.
    Holmes D
    Nature; 2015 Nov; 527(7579):S217. PubMed ID: 26605761
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel Insights into Membrane Targeting of B Cell Lymphoma.
    de Winde CM; Elfrink S; van Spriel AB
    Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics of ovarian cancer: functional insights and clinical applications.
    Elzek MA; Rodland KD
    Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitivity and chemoresistance testing.
    Markman M
    J Clin Oncol; 2005 Oct; 23(29):7363-4. PubMed ID: 16210675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.